Status
Conditions
Treatments
About
The goal of this observational study is to compare subjects with at-risk-mental-state, early psychosis, schizophrenia, depression, and autism spectrum disorders, with healthy controls (N = 21 x 6). The main questions it aims to answer are:
Participants will:
Full description
Aim of the study: EEG microstates translate the resting-state temporal dynamics of neuronal networks throughout the brain. Here, the investigators aim to see whether EEG microstate anomalies could constitute markers of psychiatric disorders.
Methods: six groups of 21 participants each will be included. There will be five groups of participants with psychiatric disorders (at-risk-mental state - ARMS, first-episode psychosis - FEP, schizophrenia - SCZ, major depressive disorder - MDD, and autism spectrum disorders - ASD) and one group of healthy controls. Our main objective is to test differences in means between the groups, at rest and during sleep, for each of the variables characterizing each of the microstates (duration, frequency, occupation time) as well as, secondarily, EEG measures of connectivity (somatosensory evoked potentials), cortical excitability (alpha-band power), and prosodic and conversational linguistic measures.
For all variables, the investigators will apply a repeated measures ANOVA, and use the following contrasts:
"ARMS, FEP, SCZ, ASD, MDD" vs. "Healthy subjects" (microstates are tested as markers of general psychopathology);
"ARMS, FEP, SCZ" vs "ASD, MDD" (microstates are tested as specific markers of psychosis; equivalently, the specificity of this signature for depression and ASD will be tested)
"ARMS" vs. "FEP" vs. "SCZ" (microstates are tested as evolutionary markers);
Finally, depending on the rate of transition to psychosis among UHRs, a comparison of "UHR-T" vs "UHR-NT" can be made (microstates are tested as predictive markers of psychosis All subjects will undergo a deep phenotyping including neuropsychology, psychopathology, neurological soft signs scales, as well as structural MRI, and genetic and epigenetic measures.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
126 participants in 6 patient groups
Loading...
Central trial contact
Anton Iftimovici, MD, PhD; Valeria Lucarini, MD, MS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal